Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 13/20 | 0.53 |
| ▸ | MMP13 | P45452 | 5/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 4/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003735 | 0.80 | BMP1 (0.61) | BMP1MMP13MMP2MMP1MMP3 | |
| SCHEMBL7112538 | 0.78 | BMP1 (0.70) | BMP1 | |
| SCHEMBL7242149 | 0.76 | BMP1 (0.61) | BMP1MMP13MMP2MMP9MMP1 | |
| SCHEMBL7001405 | 0.74 | BMP1 (0.89) | BMP1MMP13MMP1MMP3MMP8 | |
| SCHEMBL6412790 | 0.74 | MMP3 (0.66) | BMP1MMP13MMP2MMP9MMP1 | |
| SCHEMBL7002757 | 0.73 | BMP1 (0.78) | BMP1MMP13MMP2MMP9MMP1 | |
| SCHEMBL7004507 | 0.73 | BMP1 (0.65) | BMP1MMP13MMP2MMP9MMP1 | |
| SCHEMBL6420436 | 0.72 | MMP3 (0.61) | BMP1MMP13MMP2MMP9MMP1 | |
| Hydrochloric Acid SCHEMBL7347922 | 0.72 | MMP2 (0.72) | MMP13MMP2MMP9MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL7347917 | 0.72 | MMP2 (0.72) | MMP13MMP2MMP9MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | claimed |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | BMP1 730/4885MMP13 2/4885MMP2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.